Sangamo BioSciences | SGMO - Debt


Sangamo BioSciences reported $0 in Debt for its fiscal quarter ending in June of 2022.





Debt Change Date
Alaunos Therapeutics USD 10.99M 5.78M Mar/2023
Alnylam Pharmaceuticals USD 1.27B 5.33M Mar/2026
Alterity Therapeutics Limited AUD 210.39K 120.67K Jun/2023
Amgen USD 57.32B 2.72B Mar/2026
Bayer EUR 36.45B 2.93B Dec/2025
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
Biogen USD 8.09B 1.53B Jun/2026
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Cipla INR 6.14B 1.76B Mar/2026
Clal Biotechnology ILS 35.76M 28.27M Dec/2023
Compugen USD 2.93M 14K Mar/2026
CSL USD 11.96B 219M Dec/2024
Gilead Sciences USD 22.17B 2.76B Mar/2026
GlaxoSmithKline GBP 19.06B 1.34B Mar/2026
Grifols EUR 9.23B 626.05M Dec/2024
Ionis Pharmaceuticals USD 1.91B 425.5M Jun/2026
J&J USD 54.99B 7.05B Mar/2026
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
Merck USD 49.12B 222M Mar/2026
Novartis USD 49.01B 2.02B Jun/2026
Omeros USD 442.16M 199K Sep/2023
Pfizer USD 63.19B 536M Jun/2026
Roche Holding CHF 33.03B 1.41B Jun/2025
Sangamo BioSciences USD 0 0 Jun/2022
Sanofi EUR 23.58B 3.56B Jun/2026
Sarepta Therapeutics USD 1.04B 3.08M Mar/2026
Tectonic Therapeutic USD 876K 115K Dec/2024
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Vertex Pharmaceuticals USD 1.98B 8.9M Jun/2026